Citations

Clear

400 citation(s) found for "Berry, DA".

Outcomes of primary total hip arthroplasty following septic arthritis of the hip
Bettencourt, Jacob W. , Osmon, Douglas R. , Hanssen, Arlen D. , Berry, Daniel J. , Wyles, Cody C. , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 31, 2022 | Volume: 104-B | Issue: 2 | Pages: 227-234

10.1302/0301-620x.104b2.bjj-2021-1209.r1 | PMID 35094571 Get It

Aims Septic arthritis of the hip often leads to irreversible osteoarthritis (OA) and the requirement for total hip arthroplasty (THA). The aim of this study was to report the mid-term risk of any infection, periprosthetic joint infection (PJI), aseptic revision, and reoperation in patients with a past history of septic arthritis who underwent THA, compared with a control group of patients who underwent THA for OA. Methods We retrospectively identified 256 THAs in 244 patients following septic arthritis of the native hip, which were undertaken between 1969 and 2016 at a single institution. Each case was matched 1:1, based on age, sex, BMI, and year of surgery, to a primary THA performed for OA. The mean age and BMI were 58 years (35 to 84) and 31 kg/m2 (18 to 48), respectively, and 100 (39%) were female. The mean follow-up was 11 years (2 to 39). Results The ten-year survival free of any infection was 91% and 99% in the septic arthritis and OA groups, respectively (hazard ratio (HR) = 13; p < 0.001). The survival free of PJI at ten years was 93% and 99% in the septic arthritis and OA groups, respectively (HR = 10; p = 0.002). There was a significantly higher rate of any infection at ten years when THA was undertaken within five years of the diagnosis of septic arthritis compared with those in whom THA was undertaken > five years after this diagnosis was made (14% vs 5%, respectively; HR = 3.1; p = 0.009), but there was no significant difference in ten-year survival free of aseptic revision (HR = 1.14; p = 0.485). The mean Harris Hip Scores at two and five years postoperatively were significantly lower in the septic arthritis group compared with the OA group (p = 0.001 for both). Conclusion There was a ten-fold increased risk of PJI in patients with a history of septic arthritis who underwent THA compared with those who underwent THA for OA with a ten-year cumulative incidence of 7%. The risk of any infection had a strong downward trend as the time interval between the diagnosis of septic arthritis and THA increased, highlighted by a 3.1-fold higher risk when THAs were performed within five years of the diagnosis being made. Cite this article: Bone Joint J 2022;104-B(2):227–234.
Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses
Miller, Robert G. , Zhang, Rongzhen , Bracci, Paige M. , Azhir, Ari, Barohn, Richard J., Bedlack, Richard , Benatar, Michael , Cudkowicz, Merit , Kasarskis, Edward J. , Mitsumoto, Hiroshi , Manousakis, Georgios , Walk, David , Oskarsson, Björn , McGrath, Michael S. , McGrath, Michael S , Oskarsson, Björn , Bedlack, Richard S , Cudkowicz, Merit E , Walk, David , Berry, James D. , Shefner, Jeremy M.

Mayo Clinic

Muscle & Nerve | January 31, 2022 | Volume: 66 | Issue: 1 | Pages: 39-49

10.1002/mus.27511 | PMID 35098554 Get It

AbstractIntroduction/AimsALS is a heterogeneous disease that may be complicated or in part driven by inflammation. NP001, a regulator of macrophage activation, was associated with slowing disease progression in those with higher levels of the plasma inflammatory marker C‐reactive protein (CRP) in phase 2A studies in ALS. Here, we evaluate the effects of NP001 in a phase 2B trial, and perform a post hoc analysis with combined data from the preceding phase 2A trial.MethodsThe phase 2B trial enrolled 138 participants within 3 y of symptom onset and with plasma hs‐CRP values >1.13 mg/L. They were randomized 1:1 to receive either placebo or NP001 for 6 mo. Change from baseline ALSFRS‐R scores was the primary efficacy endpoint. Secondary endpoints included vital capacity (VC) change from baseline and percentage of participants showing no decline of ALSFRS‐R score over 6 mo (non‐progressor).ResultsThe phase 2B study did not show significant differences between placebo and active treatment with respect to change in ALSFRS‐R scores, or VC. The drug was safe and well tolerated. A post hoc analysis identified a 40‐ to 65‐y‐old subset in which NP001‐treated patients demonstrated slower declines in ALSFRS‐R score by 36% and VC loss by 51% compared with placebo. A greater number of non‐progressors were NP001‐treated compared with placebo (p = .004).DiscussionAlthough the phase 2B trial failed to meet its primary endpoints, post hoc analyses identified a subgroup whose decline in ALSFRS‐R and VC scores were significantly slower than placebo. Further studies will be required to validate these findings.
Intra-articular celecoxib improves knee extension regardless of surgical release in a rabbit model of arthrofibrosis
Trousdale, William H., Limberg, Afton K., Reina, Nicolas, Salib, Christopher G., Thaler, Roman, Dudakovic, Amel, Berry, Daniel J., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Wijnen, Andre van, Abdel, Matthew P., Berry, Daniel J. , Wijnen, André J. van , van Wijnen, Andre J , Berry, Daniel J , Trousdale, William H., Limberg, Afton K., Reina, Nicolas, Salib, Christopher G., Thaler, Roman, Dudakovic, Amel, Berry, Daniel J., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Abdel, Matthew P.

Mayo Clinic

Bone & Joint Research | January 27, 2022 | Volume: 11 | Issue: 1 | Pages: 32-39

10.1302/2046-3758.111.bjr-2021-0546.r1 | PMID 35084209 Get It

Aims Outcomes of current operative treatments for arthrofibrosis after total knee arthroplasty (TKA) are not consistently positive or predictable. Pharmacological in vivo studies have focused mostly on prevention of arthrofibrosis. This study used a rabbit model to evaluate intra-articular (IA) effects of celecoxib in treating contracted knees alone, or in combination with capsular release. Methods A total of 24 rabbits underwent contracture-forming surgery with knee immobilization followed by remobilization surgery at eight weeks. At remobilization, one cohort underwent capsular release (n = 12), while the other cohort did not (n = 12). Both groups were divided into two subcohorts (n = 6 each) – one receiving IA injections of celecoxib, and the other receiving injections of vehicle solution (injections every day for two weeks after remobilization). Passive extension angle (PEA) was assessed in live rabbits at 10, 16, and 24 weeks, and disarticulated limbs were analyzed for capsular stiffness at 24 weeks. Results IA celecoxib resulted in greater mean PEA at ten weeks (69.6° (SD 4.6) vs 45.2° (SD 9.6), p = 0.004), 16 weeks (109.8° (SD 24.2) vs 60.9° (SD10.9), p = 0.004), and 24 weeks (101.0° (SD 8.0) vs 66.3° (SD 5.8), p = 0.004). Capsular stiffness was significantly reduced with IA celecoxib (2.72 Newton per cm (N·cm)/° (SD 1.04), p = 0.008), capsular release (2.41 N·cm/° (SD 0.80), p = 0.008), and capsular release combined with IA celecoxib (3.56 N·cm/° (SD 0.99), p = 0.018) relative to IA vehicle (6.09 N·cm/° (SD 1.64)). Conclusion IA injections of a celecoxib led to significant improvements in passive extension angles, with reduced capsular stiffness, when administered to rabbit knees with established experimental contracture. Celecoxib was superior to surgical release, and the combination of celecoxib and a surgical release did not provide any additional value. Cite this article: Bone Joint Res 2022;11(1):32–39.
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS
Katz, Jonathan, Cudkowicz, Merit , Genge, Angela , Oskarsson, Björn , Hains, Avis B., Galanter, Joshua , Burgess, Braydon L., Kerchner, Geoffrey A. , Yeh, Felix L. , Ghosh, Arundhati Sengupta, Cheeti, Sravanthi , Brooks, Logan , Honigberg, Lee , Couch, Jessica A. , Rothenberg, Michael E. , Brunstein, Flávia, Sharma, Khema R., Berg, Leonard van den , Glass, Jonathan D. , Glass, Jonathan D , Oskarsson, Björn , Cudkowicz, Merit E , Rothstein, Jeffrey D. , Chen, Chen , Cho, Yong‐Yeon , Brooks, Logan, Berry, James D.

Mayo Clinic

Annals of Clinical and Translational Neurology | January 11, 2022 | Volume: 9 | Issue: 1 | Pages: 50-66

10.1002/acn3.51491 | PMID 35014217 Get It

AbstractObjectiveDual leucine zipper kinase (DLK), which regulates the c‐Jun N‐terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS). This first‐in‐human study investigated safety, tolerability, and pharmacokinetics (PK) of oral GDC‐0134, a small‐molecule DLK inhibitor. Plasma neurofilament light chain (NFL) levels were explored in GDC‐0134‐treated ALS patients and DLK conditional knockout (cKO) mice.MethodsThe study included placebo‐controlled, single and multiple ascending‐dose (SAD; MAD) stages, and an open‐label safety expansion (OLE) with adaptive dosing for up to 48 weeks.ResultsForty‐nine patients were enrolled. GDC‐0134 (up to 1200 mg daily) was well tolerated in the SAD and MAD stages, with no serious adverse events (SAEs). In the OLE, three study drug‐related SAEs occurred: thrombocytopenia, dysesthesia (both Grade 3), and optic ischemic neuropathy (Grade 4); Grade ≤2 sensory neurological AEs led to dose reductions/discontinuations. GDC‐0134 exposure was dose‐proportional (median half‐life = 84 h). Patients showed GDC‐0134 exposure‐dependent plasma NFL elevations; DLK cKO mice also exhibited plasma NFL compared to wild‐type littermates.InterpretationThis trial characterized GDC‐0134 safety and PK, but no adequately tolerated dose was identified. NFL elevations in GDC‐0134‐treated patients and DLK cKO mice raised questions about interpretation of biomarkers affected by both disease and on‐target drug effects. The safety profile of GDC‐0134 was considered unacceptable and led to discontinuation of further drug development for ALS. Further work is necessary to understand relationships between neuroprotective and potentially therapeutic effects of DLK knockout/inhibition and NFL changes in patients with ALS.
Disease progression models of familial frontotemporal lobar degeneration and the temporal ordering of biomarker changes in an international cohort
Staffaroni, Adam M. , Quintana, Melanie , Petrucelli, Leonard , Goh, Sheng‐Yang Matthew, Wolf, Amy , Heuer, Hilary W. , Ong, Elise, Forsberg, Leah K. , Brushaber, Danielle , Bahl, Riley, Heller, Carolin , Bouzigues, Arabella , Swift, Imogen J. , Bocchetta, Martina , Rosen, Howard J. , Boxer, Adam L. , GENFI, ALLFTD and, Bocchetta, Martina , Bouzigues, Arabella , Wendelberger, Barbara , Russell, Lucy L. , Gendron, Tania F. , Cobigo, Yann , Cash, David M. , Peakman, Georgia , Todd, Emily G. , Convery, Rhian , Boeve, Bradley F. , Rohrer, Jonathan D. , GENFI, ALLFTD and

Mayo Clinic

Alzheimer's & Dementia | December 31, 2021 | Volume: 17 | Issue: S5 | Pages: No page available

10.1002/alz.055353 Get It

AbstractBackgroundClinical trials are underway to treat familial frontotemporal lobar degeneration (f‐FTLD). This is a rare disease, and a limited number of mutation carriers have been identified; thus, efficient trial design is critical. Multimodal, latent disease progression models (DPM) can estimate time to symptom onset and define the temporal ordering of biomarker changes. DPMs can also be leveraged to select endpoints and potentially supplement analyses by integrating historical data. Recent draft FDA guidance for gene therapy trials in neurological disease supports these novel approaches to clinical trials.MethodParticipants included 1,049 members of families affected by f‐FTLD, due to mutations in GRN, MAPT, or C9orf72 genes, who were enrolled in ALLFTD or GENFI. A Bayesian repeated measures model incorporated multimodal data to estimate disease progression, conditional on latent disease age (proximity to symptom onset), in 677 mutations carriers (GRN (n=233), MAPT (n=151) and C9orf72 (n=293)). Family members without pathogenic mutations were used as the reference group. Mean follow‐up was 1.1 (SD=1.1) years. Jointly modeled longitudinal variables included neuropsychological scores, CDR®+NACC‐FTLD Box Score, MRI volumes of brain regions affected by f‐FTLD, and plasma levels of neurofilament light chain (NfL).ResultDisease progression curves were similar across ALLFTD and GENFI cohorts. Plasma NfL elevations occurred earliest, up to 10 years before symptom onset, and NfL was the most powerful endpoint in the asymptomatic stage. MRI abnormalities occurred next, closer to symptom onset. The earliest MRI changes relative to symptom onset were observed in C9orf72+. GRN mutation carriers showed the most rapid acceleration in all biomarkers, and this acceleration occurred in close proximity to symptom onset. Neuropsychological measures and CDR®+NACC‐FTLD Box Score were among the most promising endpoints in the symptomatic stage. Trial simulations indicated that using latent disease age as an enrollment criterion would allow some asymptomatic mutation carriers to be enrolled without sacrificing power.ConclusionSimilarity in disease progression across ALLFTD and GENFI participants suggests these models will apply to international trials. Model‐derived estimates of disease progression curves indicate that endpoint selection should be specific to disease stage and mutation, and DPMs would facilitate greater participant enrollment.
Redefining the 3D Topography of the Acetabular Safe Zone
Hevesi, Mario, Wyles, Cody C. , Rouzrokh, Pouria , Erickson, Bradley J. , Kremers, Hilal Maradit , Lewallen, David G. , Taunton, Michael J. , Trousdale, Robert T. , Berry, Daniel J. , Hevesi, Mario , Maradit-Kremers, Hilal, Maradit Kremers, Hilal , Erickson, Bradley J , Taunton, Michael J , Wyles, Cody C , Rouzrokh, Pouria , Berry, Daniel J , Hevesi, Mario , Hevesi, Mario

Mayo Clinic

Journal of Bone and Joint Surgery | December 27, 2021 | Volume: 104 | Issue: 3 | Pages: 239-245

10.2106/jbjs.21.00406 | PMID 34958643 Get It

Background: Dislocation is the most common reason for early revision following total hip arthroplasty (THA). More than 40 years ago, Lewinnek et al. proposed an acetabular “safe zone” to avoid dislocation. While novel at the time, their study was substantially limited according to modern standards. The purpose of this study was to determine optimal acetabular cup positioning during THA as well as the effect of surgical approach on the topography of the acetabular safe zone and the hazard of dislocation. Methods: Primary THAs that had been performed at a single institution from 2000 to 2017 were reviewed. Acetabular inclination and anteversion were measured using an artificial intelligence neural network; they were validated with performance testing and comparison with blinded grading by 2 orthopaedic surgeons. Patient demographics and dislocation were noted during follow-up. Multivariable Cox proportional-hazards regression, including multidimensional analysis, was performed to define the 3D topography of the acetabular safe zone and its association with surgical approach. Results: We followed 9,907 THAs in 8,081 patients (4,166 women and 3,915 men; 64 ± 13 years of age) for a mean of 5 ± 3 years (range: 2 to 16); 316 hips (3%) sustained a dislocation during follow-up. The mean acetabular inclination was 44° ± 7° and the mean anteversion was 32° ± 9°. Patients who did not sustain a dislocation had a mean anteversion of 32° ± 9° (median, 32°), with the historic ideal anteversion of 15° observed to be only in the third percentile among non-dislocating THAs (p < 0.001). Multivariable modeling demonstrated the lowest dislocation hazards at an inclination of 37° and an anteversion of 27°, with an ideal modern safe zone of 27° to 47° of inclination and 18° to 38° of anteversion. Three-dimensional analysis demonstrated a similar safe-zone location but significantly different safe-zone topography among surgical approaches (p = 0.03) and sexes (p = 0.02). Conclusions: Optimal acetabular positioning differs significantly from historic values, with increased anteversion providing decreased dislocation risk. Additionally, surgical approach and patient sex demonstrated clear effects on 3D safe-zone topography. Further study is needed to characterize the 3D interaction between acetabular positioning and spinopelvic as well as femoral-sided parameters. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
Factors Affecting the Risk of Aseptic Patellar Complications in Primary TKA Performed with Cemented All-Polyethylene Patellar Resurfacing
Limberg, Afton K. , Tibbo, Meagan E. , Ollivier, Matthieu , Tammachote, Nattapol , Abdel, Matthew P. , Berry, Daniel J. , Abdel, Matthew P , Berry, Daniel J , Limberg, Afton K. , Tibbo, Meagan E. , Ollivier, Matthieu , Tammachote, Nattapol

Mayo Clinic

Journal of Bone and Joint Surgery | December 21, 2021 | Volume: 104 | Issue: 5 | Pages: 451-458

10.2106/jbjs.21.00356 | PMID 34932523 Get It

Background: Patellar complications are a consequential cause of failure of primary total knee arthroplasty (TKA). The purpose of this study was to evaluate the association of demographic and patient factors with the long-term risk of patellar complications as a function of time in a very large cohort of primary TKAs performed with patellar resurfacing. Methods: We identified 27,192 primary TKAs utilizing cemented all-polyethylene patellar components that were performed at a single institution from 1977 through 2015. We evaluated the risk of any aseptic patellar complication and any aseptic patellar reoperation or revision, subanalyzed risks of reoperation or revision for loosening, maltracking/instability, and wear, and evaluated the risk of clinical diagnosis of patellar fracture and clunk/crepitus. The mean age at TKA was 68 years (range, 18 to 99 years); 57% of the patients were female. The mean body mass index (BMI) was 32 kg/m 2 . The primary diagnosis was osteoarthritis in 83%, and 70% of the TKAs were posterior-stabilized. Median follow-up was 7 years (range, 2 to 40 years). Risk factors for each outcome were evaluated with Cox regression models. Results: Nine hundred and seventy-seven knees with all-polyethylene patellae developed patellar complications. Survivorship free from any aseptic patellar complication was 93.3% at 20 years. Twenty-year survivorship free from any aseptic patellar reoperation was 97.3% and free from any aseptic patellar revision was 97.4%. Fifteen-year survivorship for the same end points for procedures performed from 2000 to 2015 was 95.7%, 99.2% and 99.3% respectively, representing substantial improvements compared with implants placed before 2000. Univariate analysis demonstrated that male sex (hazard ratio [HR], 1.4), an age of <65 years (HR, 1.3), and a BMI of ≥30 kg/m 2 (HR, 1.2) were associated with increased risk of patellar complications (all p ≤0.01). Posterior-stabilized designs were associated with fewer patellar reoperations and revisions overall (HR, 0.4 and 0.4; p < 0.001) but higher risk of patellar clunk/crepitus (HR, 14.1; p < 0.001). Conclusions: The 20-year survivorship free from any aseptic patellar complication in this series of cemented all-polyethylene patellae was 93%. Important risk factors for any aseptic patellar complication were male sex, an age of <65 years, a BMI of ≥30 kg/m 2 , and a patella implanted before 2000. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
1099: RECURRENT HEMOPTYSIS AND NEOVASCULARIZATION: A DANGEROUS COMPLICATION OF FIBROSING MEDIASTINITIS
Martin, Max, Marion, Joseph , Moraes, Alice Gallo de

Mayo Clinic

Critical Care Medicine | December 16, 2021 | Volume: 50 | Issue: 1 | Pages: 548-548

10.1097/01.ccm.0000810720.99199.a5 Get It

A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
Cudkowicz, Merit , Lindborg, Stacy , Goyal, Namita , Miller, Robert G. , Burford, Matthew, Nicholson, Katharine, Mozaffar, Tahseen , Katz, Jonathan, Jenkins, Liberty, Baloh, Robert H. , Lewis, Richard A. , Staff, N., Owegi, Margaret, Berry, Donald A. , Gothelf, Yaël, Levy, Yossef S., Aricha, Revital , Kern, R. , Windebank, Anthony J. , Brown, Robert H. , Staff, Nathan P. , Cudkowicz, Merit E , Lindborg, Stacy R , Mozaffar, Tahseen , Lewis, Richard A , Brown, Robert H , Staff, Nathan P , Berry, James D.

Mayo Clinic

Muscle & Nerve | December 10, 2021 | Volume: 65 | Issue: 3 | Pages: 291-302

10.1002/mus.27472 | PMID 34890069 Get It

Abstract Introduction/Aims Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC‐NTF), a novel autologous cell‐therapy capable of targeting multiple pathways, could safely slow ALS disease progression. Methods This randomized, double‐blind, placebo‐controlled study enrolled ALS participants meeting revised El Escorial criteria, revised ALS Functional Rating Scale (ALSFRS‐R) ≥25 (screening) and ≥3 ALSFRS‐R points decline prior to randomization. Participants received three treatments of MSC‐NTF or placebo intrathecally. The primary endpoint evaluated efficacy of MSC‐NTF through a responder analysis and safety. A change in disease progression post‐treatment of ≥1.25 points/mo defines a clinical response. A pre‐specified analysis leveraged baseline ALSFRS‐R of 35 as a subgroup threshold. Results Overall, MSC‐NTF treatment was well tolerated; there were no safety concerns. Thirty‐three percent of MSC‐NTF and 28% of placebo participants met clinical response criteria at 28 wk (odds ratio [OR] = 1.33, P = .45); thus, the primary endpoint was not met. A pre‐specified analysis of participants with baseline ALSFRS‐R ≥ 35 (n = 58) showed a clinical response rate at 28 wk of 35% MSC‐NTF and 16% placebo (OR = 2.6, P = .29). Significant improvements in cerebrospinal biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support were observed with MSC‐NTF, with placebo unchanged. Discussion The study did not reach statistical significance on the primary endpoint. However, a pre‐specified subgroup suggests that MSC‐NTF participants with less severe disease may have retained more function compared to placebo. Given the unmet patient need, the results of this trial warrant further investigation.